155 related articles for article (PubMed ID: 37423578)
1. Critical nanomaterial attributes of iron-carbohydrate nanoparticles: Leveraging orthogonal methods to resolve the 3-dimensional structure.
Krupnik L; Joshi P; Kappler A; Flühmann B; Alston AB; Digigow R; Wick P; Neels A
Eur J Pharm Sci; 2023 Sep; 188():106521. PubMed ID: 37423578
[TBL] [Abstract][Full Text] [Related]
2. Iron-carbohydrate complexes treating iron anaemia: Understanding the nano-structure and interactions with proteins through orthogonal characterisation.
Krupnik L; Avaro J; Liebi M; Anaraki NI; Kohlbrecher J; Sologubenko A; Handschin S; Rzepiela AJ; Appel C; Totu T; Blanchet CE; Alston AEB; Digigow R; Philipp E; Flühmann B; Silva BFB; Neels A; Wick P
J Control Release; 2024 Apr; 368():566-579. PubMed ID: 38438093
[TBL] [Abstract][Full Text] [Related]
3. Factors influencing safety and efficacy of intravenous iron-carbohydrate nanomedicines: From production to clinical practice.
Nikravesh N; Borchard G; Hofmann H; Philipp E; Flühmann B; Wick P
Nanomedicine; 2020 Jun; 26():102178. PubMed ID: 32145382
[TBL] [Abstract][Full Text] [Related]
4. Snapshots of Iron Speciation: Tracking the Fate of Iron Nanoparticle Drugs via a Liquid Chromatography-Inductively Coupled Plasma-Mass Spectrometric Approach.
Neu HM; Alexishin SA; Brandis JEP; Williams AMC; Li W; Sun D; Zheng N; Jiang W; Zimrin A; Fink JC; Polli JE; Kane MA; Michel SLJ
Mol Pharm; 2019 Mar; 16(3):1272-1281. PubMed ID: 30676753
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the Physicochemical Properties of the Iron Nanoparticle Drug Products: Brand and Generic Sodium Ferric Gluconate.
Brandis JEP; Kihn KC; Taraban MB; Schnorr J; Confer AM; Batelu S; Sun D; Rodriguez JD; Jiang W; Goldberg DP; Langguth P; Stemmler TL; Yu YB; Kane MA; Polli JE; Michel SLJ
Mol Pharm; 2021 Apr; 18(4):1544-1557. PubMed ID: 33621099
[TBL] [Abstract][Full Text] [Related]
6. Dynamic Light Scattering Analysis for the Determination of the Particle Size of Iron-Carbohydrate Complexes.
Burgert M; Marques CB; Borchard G; Philipp E; Wilhelm M; Alston A; Digigow R
J Vis Exp; 2023 Jul; (197):. PubMed ID: 37486118
[TBL] [Abstract][Full Text] [Related]
7. The Nano-Bio Interactions of Nanomedicines: Understanding the Biochemical Driving Forces and Redox Reactions.
Wang Y; Cai R; Chen C
Acc Chem Res; 2019 Jun; 52(6):1507-1518. PubMed ID: 31149804
[TBL] [Abstract][Full Text] [Related]
8. Measuring particle size distribution of nanoparticle enabled medicinal products, the joint view of EUNCL and NCI-NCL. A step by step approach combining orthogonal measurements with increasing complexity.
Caputo F; Clogston J; Calzolai L; Rösslein M; Prina-Mello A
J Control Release; 2019 Apr; 299():31-43. PubMed ID: 30797868
[TBL] [Abstract][Full Text] [Related]
9. Criticality of Surface Characteristics of Intravenous Iron-Carbohydrate Nanoparticle Complexes: Implications for Pharmacokinetics and Pharmacodynamics.
Funk F; Flühmann B; Barton AE
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216261
[TBL] [Abstract][Full Text] [Related]
10. Measuring particle concentration of multimodal synthetic reference materials and extracellular vesicles with orthogonal techniques: Who is up to the challenge?
Vogel R; Savage J; Muzard J; Camera GD; Vella G; Law A; Marchioni M; Mehn D; Geiss O; Peacock B; Aubert D; Calzolai L; Caputo F; Prina-Mello A
J Extracell Vesicles; 2021 Jan; 10(3):e12052. PubMed ID: 33473263
[TBL] [Abstract][Full Text] [Related]
11. Core size determination and structural characterization of intravenous iron complexes by cryogenic transmission electron microscopy.
Wu Y; Petrochenko P; Chen L; Wong SY; Absar M; Choi S; Zheng J
Int J Pharm; 2016 May; 505(1-2):167-74. PubMed ID: 27001529
[TBL] [Abstract][Full Text] [Related]
12. Putting square pegs in round holes: Why traditional pharmacokinetic principles cannot universally be applied to iron-carbohydrate complexes.
Alston AB; Digigow R; Flühmann B; Wacker MG
Eur J Pharm Biopharm; 2023 Jul; 188():6-14. PubMed ID: 37142131
[TBL] [Abstract][Full Text] [Related]
13. Nanomedicines in clinical practice: Are colloidal iron sucrose ready-to-use intravenous solutions interchangeable?
Di Francesco T; Sublet E; Borchard G
Eur J Pharm Sci; 2019 Apr; 131():69-74. PubMed ID: 30742979
[TBL] [Abstract][Full Text] [Related]
14. Measuring Particle Size Distribution by Asymmetric Flow Field Flow Fractionation: A Powerful Method for the Preclinical Characterization of Lipid-Based Nanoparticles.
Caputo F; Arnould A; Bacia M; Ling WL; Rustique E; Texier I; Mello AP; Couffin AC
Mol Pharm; 2019 Feb; 16(2):756-767. PubMed ID: 30604620
[TBL] [Abstract][Full Text] [Related]
15. Role of Particle Size in Translational Research of Nanomedicines for Successful Drug Delivery: Discrepancies and Inadequacies.
Chan HW; Chow S; Zhang X; Kwok PCL; Chow SF
J Pharm Sci; 2023 Sep; 112(9):2371-2384. PubMed ID: 37453526
[TBL] [Abstract][Full Text] [Related]
16. Characterization Challenges of Self-Assembled Polymer-SPIONs Nanoparticles: Benefits of Orthogonal Methods.
Marques C; Maurizi L; Borchard G; Jordan O
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555765
[TBL] [Abstract][Full Text] [Related]
17. Regulatory challenges of nanomedicines and their follow-on versions: A generic or similar approach?
Mühlebach S
Adv Drug Deliv Rev; 2018 Jun; 131():122-131. PubMed ID: 29966685
[TBL] [Abstract][Full Text] [Related]
18. Biophysicochemical perspective of nanoparticle compatibility: a critically ignored parameter in nanomedicine.
Hassan S; Singh AV
J Nanosci Nanotechnol; 2014 Jan; 14(1):402-14. PubMed ID: 24730271
[TBL] [Abstract][Full Text] [Related]
19. Physicochemical Characterization of Iron Carbohydrate Colloid Drug Products.
Zou P; Tyner K; Raw A; Lee S
AAPS J; 2017 Sep; 19(5):1359-1376. PubMed ID: 28762128
[TBL] [Abstract][Full Text] [Related]
20. A robust and easily reproducible protocol for the determination of size and size distribution of iron sucrose using dynamic light scattering.
Di Francesco T; Borchard G
J Pharm Biomed Anal; 2018 Apr; 152():89-93. PubMed ID: 29414023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
